Lang C, Lukasewitz P, Wulf H, Geldner G
Klinik für Anästhesie und Intensivtherapie, Klinikum der Philipps-Universität Marburg, Baldingerstrasse, 35033 Marburg/Lahn.
Anaesthesist. 2002 Feb;51(2):134-41. doi: 10.1007/s00101-001-0276-3.
Succinylcholine and mivacurium are degraded more slowly in patients with a qualitatively or quantitatively reduced plasma cholinesterase and are therefore known for inducing a prolonged postoperative apnea. Perioperative laboratory screening even including plasma cholinesterase activity testing will not prevent this due to a possible aberration only in the qualitative cholinesterase activity. This is illustrated by introducing two cases reports of prolonged apnea after administration of mivacurium or succinylcholine. The pathophysiology of plasma cholinesterase is reviewed including genetically determined variants and the degradation pathways of mivacurium and succinylcholine. Only extensive laboratory chemical tests are sufficient to prevent this possible complication. Due to the rare incidence there is no evidence for recommending these laboratory investigations in all patients. Once prolonged apnea occurs following the administration of mivacurium or succinylcholine the best choice is ongoing ventilation combined with a sufficient sedation.
在血浆胆碱酯酶定性或定量降低的患者中,琥珀酰胆碱和米库氯铵的降解更慢,因此以引起术后呼吸暂停时间延长而闻名。围手术期实验室筛查,甚至包括血浆胆碱酯酶活性检测,由于可能仅在定性胆碱酯酶活性方面存在异常,所以无法预防这种情况。通过引入两例米库氯铵或琥珀酰胆碱给药后呼吸暂停延长的病例报告来说明这一点。回顾了血浆胆碱酯酶的病理生理学,包括基因决定的变体以及米库氯铵和琥珀酰胆碱的降解途径。只有广泛的实验室化学检测足以预防这种可能的并发症。由于发病率低,没有证据表明要对所有患者推荐这些实验室检查。一旦在给予米库氯铵或琥珀酰胆碱后发生呼吸暂停延长,最佳选择是持续通气并给予足够的镇静。